Sign In
Buy IONS
$55.07
+0.580 (+1.06%)
At Close: Aug 04, 2026
Ionis: 2 Drug Advancements With Potential Firsts
05:54pm, Monday, 29'th Aug 2022
A PDUFA date of January 25, 2023 has been established for possible approval of tofersen for the treatment of patients with SOD1-ALS. An NDA filing of eplontersen for the treatment of patients with ATT
Ionis (IONS) Q2 Earnings & Sales Miss Estimates, Stock Down
12:14pm, Wednesday, 10'th Aug 2022 Zacks Investment Research
Ionis (IONS) incurs a wider-than-expected loss in Q2. Its sales also miss estimates. Stock moves down in response to the results.
Ionis (IONS) Q2 Earnings & Sales Miss Estimates, Stock Down
09:47am, Wednesday, 10'th Aug 2022
Ionis (IONS) incurs a wider-than-expected loss in Q2. Its sales also miss estimates.
Ionis Pharmaceuticals, Inc. (IONS) CEO Brett Monia on Q2 2022 Results - Earnings Call Transcript
03:39pm, Tuesday, 09'th Aug 2022
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q2 2022 Earnings Conference Call August 9, 2022 11:30 AM ET Company Participants Brett Monia - Chief Executive Officer Beth Hougen - Chief Financial Officer
Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Lags Revenue Estimates
12:15pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of -21.31% and 9.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Lags Revenue Estimates
09:47am, Tuesday, 09'th Aug 2022
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of -21.31% and 9.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Ionis Pharma Extends Breakout; Biotech Restates Guide Despite Quarterly Miss
08:58am, Tuesday, 09'th Aug 2022
Ionis Pharmaceuticals broadly missed second-quarter expectations Tuesday but reiterated its 2022 outlook and IONS stock inched up. The post Ionis Pharma Extends Breakout; Biotech Restates Guide Despit
The Zacks Analyst Blog Highlights Take-Two Interactive Software, Ionis Pharmaceuticals, Celsius Holdings, Grocery Outlet Holding and Lemonade
01:22pm, Monday, 08'th Aug 2022 Zacks Investment Research
Take-Two Interactive Software, Ionis Pharmaceuticals, Celsius Holdings, Grocery Outlet Holding and Lemonade are part of Zacks top Analyst Blog.
Why Ionis Pharmaceuticals (IONS) Might Surprise This Earnings Season
12:58pm, Monday, 08'th Aug 2022 Zacks Investment Research
Ionis Pharmaceuticals (IONS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Why Ionis Pharmaceuticals (IONS) Might Surprise This Earnings Season
10:33am, Monday, 08'th Aug 2022
Ionis Pharmaceuticals (IONS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Ironwood (IRWD) Q2 Earnings Miss, Keeps 2022 Sales Guidance
03:45pm, Friday, 05'th Aug 2022 Zacks Investment Research
Ironwood (IRWD) miss earnings and revenue estimates in the second quarter. Stock declines.
5 Stocks to Buy Ahead of Earnings Results Next Week
11:02am, Friday, 05'th Aug 2022 Zacks Investment Research
Five companies are slated to beat earnings estimates next week. These are: TTWO, IONS, CELH, LMND and GO.
5 Stocks to Buy Ahead of Earnings Results Next Week
08:17am, Friday, 05'th Aug 2022
Five companies are slated to beat earnings estimates next week. These are: TTWO, IONS, CELH, LMND and GO.
Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates
11:25pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Theravance Bio (TBPH) delivered earnings and revenue surprises of 33.33% and 36.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zoetis' (ZTS) Q2 Earnings Miss Estimates, Revenues Up
05:38pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Zoetis' (ZTS) earnings miss estimates in second-quarter 2022. The revenues beat estimates owing to the strong uptake of the company's companion animal portfolio products.
